
SeekingAlpha · 9 de sept de 2026
Biogen Inc. (BIIB) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 9:30 AM EDTCompany ParticipantsRobin Kramer - Executive VP & CFOAdam...
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Últimos 200 días · 12/11/25 — 09/09/26
+37.74%
Precio
$ 26.260
Var. %
+1,94%
Volumen operado
1.471
Precio BIIB
US$ 215,31
Teórico (precio / ratio)
BIIB ÷ 13
US$ 16,56
Sí, existe el CEDEAR de BIIB (Biogen Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es BIIB.
El ticker del CEDEAR de Biogen Inc. en Argentina es BIIB. La acción subyacente cotiza en NASDAQ con el símbolo BIIB.
El CEDEAR BIIB tiene un ratio de 13:1. Eso significa que 13 CEDEARs equivalen a 1 acción de BIIB.
El CEDEAR BIIB cotiza hoy a $ 26.260 en pesos argentinos, con una variación diaria de +1,94%.
La acción subyacente BIIB (Biogen Inc.) cotiza a US$ 215,31 en su mercado de origen (NASDAQ).

SeekingAlpha · 9 de sept de 2026
Biogen Inc. (BIIB) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 9:30 AM EDTCompany ParticipantsRobin Kramer - Executive VP & CFOAdam...

CNBC · 9 de sept de 2026
Biogen CEO Christopher Viehbacher joins 'Squawk on the Street' to discuss their upcoming product pipeline, developments in Alzheimer treatment and medication an…
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 17,12
vs teórico
+3,37%
Cotización MEP implícita
$ 1.533,88
Cotización
—
vs teórico
—
Cotización Cable implícita
—
El precio teórico del CEDEAR BIIB se calcula dividiendo el precio de BIIB por el ratio (13). Hoy resulta en US$ 16,56.
En BYMA podés operar BIIB en pesos, BIIBD en dólar MEP y BIIBC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR BIIB en pesos argentinos, con datos de data912.
FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Techn…

Yahoo · 8 de sept de 2026
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.

Yahoo · 4 de sept de 2026
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.

Yahoo · 4 de sept de 2026
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo · 4 de sept de 2026
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Sa…
Benzinga · 4 de sept de 2026
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine,…
Noticias vía Finnhub